Interactions in hepatic tumor microenvironment: Potential targets and modulations for effective therapy

Area of Science:

• Oncology
• Immunology
• Cell Biology

Background:

• The hepatic tumor microenvironment (TME) is a complex network of cellular and extracellular components.
• Hepatocellular carcinoma (HCC) cells interact with stromal cells and the extracellular matrix (ECM), fostering an immunosuppressive and pro-tumorigenic milieu.
• Key cellular players include cancer-associated fibroblasts (CAFs), activated stellate cells, tumor-associated macrophages (TAMs), regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), and Kupffer cells, all contributing to immune evasion and tumor progression.

Purpose of the Study:

• To analyze critical cellular interactions within the hepatic TME.
• To evaluate emerging therapeutic strategies targeting these interactions for improved treatment outcomes in hepatocellular carcinoma.

Main Methods:

• Review of recent studies identifying key molecular mediators in hepatic TME cellular networks.
• Analysis of preclinical data on various targeting strategies, including immune checkpoint inhibitors (ICIs), immunomodulators, stromal cell modulators, and matrix-degrading agents.
• Evaluation of novel approaches involving nanoparticles and natural-derived molecules with immunoregulatory effects.

Main Results:

• The hepatic TME exhibits complex cellular crosstalk, promoting tumor growth, immune suppression, and resistance to conventional therapies.
• Metabolic reprogramming, hypoxia, and ECM remodeling are critical factors influencing tumor behavior and drug response.
• Emerging strategies, including ICIs, immunomodulators, and novel agents, show promise in preclinical models by targeting TME components.

Conclusions:

• Understanding the intricate interactions within the hepatic TME is crucial for developing effective cancer therapies.
• Targeting specific cellular and molecular components of the TME offers a promising avenue for overcoming therapeutic resistance in hepatocellular carcinoma.
• Further research and clinical translation of novel TME-targeting strategies are warranted to improve patient outcomes.